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The amount of dietary monosodium glutamate (MSG) is increasing worldwide, in parallel
with the epidemics of metabolic syndrome. Parenteral administration of MSG to rodents
induces obesity, hyperglycemia, hyperlipidemia, insulin resistance, and type 2 diabetes.
However, the impact of dietary MSG is still being debated. We investigated the morphologi-
cal and functional effects of prolonged MSG consumption on rat glucose metabolism and
on pancreatic islet histology.
Methods
Eighty adult male Wistar rats were randomly subdivided into 4 groups, and test rats in each
group were supplemented with MSG for a different duration (1, 3, 6, or 9 months, n=20 for
each group). All rats were fed ad libitum with a standard rat chow and water. Ten test rats in
each group were provided MSG 2 mg/g body weight/day in drinking water and the 10
remaining rats in each group served as non-MSG treated controls. Oral glucose tolerance
tests (OGTT) were performed and serum insulin measured at 9 months. Animals were sacri-
ficed at 1, 3, 6, or 9 months to examine the histopathology of pancreatic islets.
Results
MSG-treated rats had significantly lower pancreatic β-cell mass at 1, 6 and 9 months of
study. Islet hemorrhages increased with age in all groups and fibrosis was significantly
more frequent in MSG-treated rats at 1 and 3 months. Serum insulin levels and glucose tol-
erance in MSG-treated and untreated rats were similar at all time points we investigated.
Conclusion
Daily MSG dietary consumption was associated with reduced pancreatic β-cell mass and
enhanced hemorrhages and fibrosis, but did not affect glucose homeostasis. We speculate
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that high dietary MSG intake may exert a negative effect on the pancreas and such effect
might become functionally significant in the presence or susceptibility to diabetes or NaCl;
future experiments will take these crucial cofactors into account.
Introduction
Monosodium glutamate (MSG), a sodium salt of glutamic acid, is used as a flavor enhancer in
food industry [1]. While the Food and Drug Administration (FDA) stated that MSG is safe as a
flavor enhancer, its safety as a food additive remains debated. Epidemiological studies from our
group and others reported the association of dietary MSG consumption with metabolic disor-
ders such as obesity or above average weight [2, 3], arterial hypertension [4] and metabolic syn-
drome [5], while others reported the lack of such associations [6, 7]. Nonetheless, consistent
metabolic effects of MSG have been demonstrated in animal studies. First, subcutaneous (SC)
MSG injections (2mg/g body weight) given to newborn mice result in central obesity and mod-
erate to severe microvesicular fatty changes throughout the liver parenchyma at 6 months [8].
Second, the same dose causes the elevation of fasting blood glucose levels and ultimately type 2
diabetes [9]. Third, higher doses of parenteral MSG (4 mg/g body weight) in mice cause insulin
resistance as illustrated by the significant increase in plasma glucose following the oral glucose
tolerance test (OGTT) and severe visceral fat accumulation [10]. Pathology in these models
showed pancreatic islets hypertrophy [9], hyperplasia [11]and decreased α-, and somatostatin
cells [12].
Despite these lines of evidence, the effects of dietary consumption of MSG are less clear, par-
ticularly the effect on pancreas histology in which numerous factors have been widely investi-
gated and should be taken into account [13, 14]. We therefore investigated the effects of oral
MSG supplementation on the rat pancreatic islets. We demonstrated significant changes in the
pancreas as early as after one month of MSG supplementation. These changes increased with




Eighty male Wistar rats (weight 150–200g) were obtained at 5 weeks of age from the National
Laboratory Animal Center, Salaya, Mahidol University, Thailand. Rats were housed in light
and temperature controlled environment at the Northeast Laboratory Animal Center
(NELAC) for 1 week before starting the experiment.
All procedures were performed in accordance with the guidelines of the Northeast Labora-
tory Animal Center (NELAC), Khon Kaen University, Thailand, and were approved (AEKKU
24/2554) by the Animal Ethics Committee of Khon Kaen University, Thailand.
Experimental design
Rats were maintained under controlled laboratory conditions at the temperature of 25±3°C
with 60±15% humidity and 12 h dark/light cycle. All rats were fed ad libitum with a standard
rat chow pellet (Perfect Companion Group, Bangkok, Thailand) and provided drinking water
purified by reverse osmosis (RO), either with or without MSG.
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Eighty rats were randomly arrayed into four groups to be observed for1, 3, 6, or 9 months,
with 20 rats in each group. Each group included control (n = 10) and MSG-treated (n = 10)
rats. MSG-treated rats were supplemented with a commercially available 99%-pure food-grade
package of MSG added to daily drinking water at the final daily dose of 2 mg/g body weight.
Food intake and body weight were recorded every one and two weeks, respectively, and rats
from different groups were sacrificed at 1, 3, 6, or 9 months following a 12-hour fasting by
intraperitoneal Nembutal injection. Blood and pancreatic tissue were collected for functional
and morphological study.
Histology and immunohistochemistry
The pancreas tail was cut and fixed with a 10% neutral buffered formalin solution. Routinely
processed paraffin-embedded tissue blocks were sliced at 4 μm thickness and sections were
stained with Haematoxylin&Eosin (H&E) and observed under a light microscope (Primo Star,
Zeiss). Prussian blue and Masson’s trichrome staining were used to determine hemosiderin
deposition and fibrosis of the islets, respectively.
Immunohistochemistry was used to identify islets β-cells and 4-hydroxynonenal (4-HNE),
respectively, using immunoperoxidase staining. Tissue sections were deparaffinized, rehydrated,
and endogenous peroxidase and non-specific binding were blocked by 0.3% H2O2 in methanol
and 3% bovine serum albumin (BSA), respectively. Sections were then incubated overnight at
room temperature with a mouse monoclonal anti-insulin (dilution 1:4000, Sigma-Aldrich,
USA) and a rabbit polyclonal anti-4-HNE (dilution 1:2000, Abcam, USA). The sections were
washed with phosphate-buffered saline (PBS, pH 7.4), and incubated 1 h at room temperature
with a goat anti-mouse IgG peroxidase antibody (dilution 1:250, Sigma-Aldrich, USA)or anti-
rabbit envision+ HRP (horse reddish peroxidase, Sigma-Aldrich, USA), washed with phosphate-
buffered saline (PBS, pH 7.4) and then stained with 3,3’-diaminobenzidine tetrahydrochloride
(DAB) (Sigma-Aldrich, USA) plus a substrate buffer solution and hydrogen peroxide.
Numbers of islets, islets sizes (μm2) and total pancreas areas (μm2) in each section were
measured by Aperio Image Scope software (version 12.0.1.5027). Islets and pancreatic tissue
boundaries were marked manually and all islets composed of 4 cells were marked. Sizes of
islets in the control groups were pooled and 5th, 10th, 25th, 50th, 75th, 90th and 95th percen-
tiles were calculated. The density of pancreatic islets (the number of islets per unit area mm2)
was calculated by the total number of islets divided by total area of pancreas in each slide,
according to the following formula.
Islets density ¼ Total number of islets
Total area of pancreas ðmm2Þ
The β-cells and 4-HNE of selected islets were analyzed by Aperio Image Scope software
using Positive Pixel Count Algorithm (Version 9.1). The positive immunoreactivity, which
produced brown color by DAB, was digitally expressed as yellow, orange and reddish-brown
color pixels in the software correlated to weak, moderate, and strongly positive, respectively,
and the negative immunoreactivity was expressed as blue color pixels. The percentage of β-
cells and 4-HNE were calculated as the equation below.
b  cell mass ð%Þ ¼ Positive pixel count
Total pixel count
 100
4  HNE ð% positivityÞ ¼ Positive pixel count
Total pixel count
 100
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Hemorrhage and ﬁbrosis in pancreatic islets were observed in H&E slides then conﬁrmed
with special staining. Erythrocytes leaked from capillaries, brown pigments deposition in/
around the islets and presence of hemosiderin were scored from mild to severe levels. The
brown pigments were conﬁrmed by the positive staining with Prussian blue. Fibrosis was con-
ﬁrmed and scored by Masson’s trichrome staining. The severity of the lesions was scored for
each islet. The incidence of hemorrhage/hemosiderin deposition and ﬁbrosis in islets were cal-
culated in each slide (20–200 islets/slide). The percentage of rats with an islet lesion was calcu-
lated by the number of rats with an islet lesion divided by the total number of rats in each
group.
To evaluate the severity of the lesions of pancreatic islets, hemorrhage/hemosiderin staining
and fibrosis were scored using the modified methods of Imaoka et al[15]. The scoring were
then categorized into positive and negative categories (score 0 = negative, score 1–3 = positive).
Percent incidence of hemorrhage, hemosiderin and fibrosis was calculated as the equation
below.
% incidence of lesions ¼ Number of islets with lesions
Total number of islets
 100
Insulin levels and oral glucose tolerance test (OGTT)
Insulin levels were determined at 1, 3, 6, and 9 months prior to sacrifice using radio immunoas-
say (RIA) kit following the manufacturer's protocol (Millipore, USA). OGTT were performed
at 9 months. After12-h overnight fasting, a glucose solution (4 g/kg body weight) was fed to the
rats. Blood samples were collected from the tail vein and glucose levels were measured at 0, 30
and 120 minutes after administration of glucose.
Statistical analyses
For statistical analyses, IBM SPSS statistics software ver.19.0.2 for Windows (KKU network
license) was used. All variables are presented as mean ± SD except for insulin levels
(mean ± SEM). Data between control and MSG-treated groups were compared by Student’s t-
test. P values0.05 were considered statistically significant.
Results
Body weight, food and water intake
Body weight and food consumption were similar in MSG-treated and untreated control rats at
1, 3, 6 and 9 months (Fig 1A and 1B), while water intake was significantly higher in the MSG-
treated groups compared to controls throughout the study period(P< 0.05) (Fig 1C).
Pancreas histopathology
Hemorrhages in the pancreatic islets were observed in both control and MSG-supplemented
groups in 4/10 and 7/10 rats at 1 month, 8/10 and 9/10at 3 months, 10/10 in both groups at 6
and 9 months, respectively (Fig 2). However, differences were not significant between the
groups throughout the study period. Pancreatic islet fibrosis also increased with age in both
groups but was more prominent in the MSG-treated group at 1 and 3 months of the study(P<
0.0001) (Fig 3). The β-cell areas in the pancreatic islets were significantly lower in the MSG-
treated group compared with controls at 1, 6 and 9 months (P< 0.05) (Fig 4). Pancreatic islet
size distribution in the MSG-treated group was significantly higher than that of the control
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groups at 1 month (Fig 5) but was similar in both groups throughout the remaining period.
The islet density of MSG-treated group was significantly higher compared to controls at 6
months (0.58 ± 0.12 vs. 0.42 ± 0.07; P<0.05), but such difference was not seen in any other
time points (Fig 6). The intensity of immune-staining of 4-HNE, an oxidative stress marker, in
the pancreatic islets of the MSG-treated group was slightly (but not significantly) higher at 1
month and was significantly higher at 6 months compared to the control group (P = 0.001)
(Fig 7).
Pancreatic functional tests
There was no significant difference in serum insulin levels between control and MSG-treated
groups at anytime point examined (Fig 8A). Similarly, OGTT performed at 9 months of study
showed no difference in glucose levels between control and MSG-treated groups (Fig 8B).
Discussion
Whether MSG intake is a causative factor in epidemics of metabolic syndrome remains largely
debated, particularly since there are epidemiological and experimental data both for and
Fig 1. Body weight (panel A), food (panel B) and water (panel C) intake in the control and MSG-treated groups at 1, 3, 6, and 9 months of study.
* P<0.05.
doi:10.1371/journal.pone.0131595.g001
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against this view. Indeed, metabolic syndrome involves insulin resistance, and pancreatic
changes should be expected. Animal studies have demonstrated that parenteral MSG causes
various changes in pancreatic islets such as hypertrophy [9], hyperplasia [11], decrease in aci-
nar cells, α-cells and somatostatin cells [12] and increase in fibrosis [16]. However, these condi-
tions do not represent the scenario of oral supplementation and for this reason we herein
investigated the effects of oral MSG on the histomorphological and functional alterations of
the rat pancreatic islets.
We report for the first time that daily consumption of dietary MSG decreases the pancreatic
β-cell mass in adult rats, similar to what has been observed following MSG injection in new-
born mice [12, 16]. However, the mechanism of the two might be different. The mechanism of
MSG-induced β-cell loss in this study remains unclear, but the increased oxidative stress by
MSG in β-cells is one possibility [17],which was supported by the increase of 4-HNE levels in
the pancreatic islets in the MSG-treated group in this study. Alloxan [18], streptozotocin (STZ)
[18], and ethanol [19]may induce β-cells loss through different mechanisms. First, in the pres-
ence of intracellular thiols, especially glutathione, alloxan generates reactive oxygen species
(ROS) in a cyclic redox reaction with its reduction product, dialuric acid. Autoxidation of dia-
luric acid generates ROS, which is in turn responsible for the β-cells necrosis [18]. Second, STZ
is separated into its glucose and methylnitroso-urea moietyinside β-cells and, due to its alkylat-
ing properties, the latter modifies biological macromolecules, fragments DNA and destroys the
β-cells, causing a state of insulin-dependent diabetes [18]. Finally, chronic ethanol
Fig 2. Representative histology (left) and prevalence (right) of islets hemorrhage/hemosiderin deposits in the control and MSG-treated group at 1,
3, 6, and 9 months (x400).
doi:10.1371/journal.pone.0131595.g002
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consumption decreases the expression and inactivation of glucokinase, a key glycolytic
enzyme,by tyrosine nitration, leading to pancreatic β-cell apoptosis [20].
We also observed islet hypertrophy in the MSG group at 1 month, similar to what reported
in mice receiving MSG injections at birth [9, 10]. Pancreatic islet hypertrophy is generally
observed in obesity and is secondary to high fat diets [21], chronic glucose infusion [22], and
partial pancreatectomy [23] followed by β-cell regeneration [24]. We speculate that similar
mechanisms may cause islet hypertrophy after oral MSG treatment. In agreement with this
observation we spot a higher density of pancreatic islets in MSG-treated rats compared to con-
trol at 6 months and expect that such density may increase the β-cell mass during regeneration.
This has been reported in mice following islet [25] and β-cell [26] injury and may represent a
reactive phenomenon in our experimental setting.
Daily consumption of MSG had minimal effects on islet hemorrhage, which in our study
increased with age regardless of MSG. This result is consistent with previous studies that
showed spontaneous hemorrhage in older males [15]. Nonetheless, the frequency of hemor-
rhage was higher with MSG consumption at 1 and 3 months and later reached a plateau, even-
tually affecting 100% of animals. It is possible that the islet hemorrhage and hemosiderin
deposition may be responsible for fibrosis that we and other groups have observed. In a previ-
ous study, male Wistar rats fed with Busulfan, an alkylating anticancer drug, developed islet
hemorrhages and islet fibrosis [27]. Fibrosis is a physiological healing process that occurs after
tissue damage/injury [28, 29]. In our study, fibrotic lesions were significantly more frequent in
Fig 3. Representative histology (left) and prevalence (right) of islet fibrosis in control and MSG-treated group at 1, 3, 6, and 9 months (Masson’s
trichrome staining, x400).
doi:10.1371/journal.pone.0131595.g003
Monosodium Glutamate Decreased Beta-Cell Mass
PLOS ONE | DOI:10.1371/journal.pone.0131595 June 29, 2015 7 / 14
the MSG-treated rats at 1 and 3 months compared to that in the controls, resembling what was
reported in rats receiving parenteral MSG at birth [16]. Similar to the hemorrhagic pattern,
fibrotic islets increased with age and aging overcome the MSG effect at later time points.
Based on the observed pathology of the pancreas, we were surprised to observe no changes
of insulin levels or glucose tolerance during MSG supplementation. We assume that the func-
tional impairment may require a second hit or a separate factor for susceptibility. Our assump-
tion based on the previous studies was that MSG was converted into 2 major products, glucose
and lactate, within two hours after ingestion [30]. Therefore, MSG consumption during meals
might increase postpandrial glucose levels and then stimulate insulin release. Indeed, MSG has
been shown to have an effect on insulin release. In human studies, serum insulin levels tended
to be higher in MSG-treated participants compared to controls and the level of serum insulin
correlated well with that of glutamate [31]. This was supported by a molecular study that
showed that glutamate transporters are expressed in pancreatic β-cells and play a role in the
regulation of insulin secretion [32]. Moreover, glutamate itself induces pancreatic β-cell dam-
age [17]. A high level of extracellular glutamate impaired the uptake of cysteine, a precursor of
glutathione synthesis, by inhibiting Glu-Cys antiporter in pancreatic β-cells, leading to oxida-
tive stress and cell death. We also observed the β-cell loss in this study. It is possible that the
dose or length of time used in this study is insufficient to induce this effect, or that the observed
effects may become significant only in the presence of a genetic susceptibility or a pre-existing
chronic condition. The use of dietary induced obese rats or genetically obese and diabetic
Fig 4. Representative immunohistochemistry (left) and prevalence (right) of insulin staining in control versus MSG-treated groups at 1, 3, 6, and 9
months (x400). * P<0.05.
doi:10.1371/journal.pone.0131595.g004
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Fig 5. Islet size (um2) distribution in control and MSG-treated groups at 1, 3, 6, and 9 months.
doi:10.1371/journal.pone.0131595.g005
Fig 6. Islet density in control and MSG-treated groups at 1, 3, 6, and 9months.
doi:10.1371/journal.pone.0131595.g006
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Zucker rats will be useful to further evaluate the effect of MSG on glucose homeostasis, pancre-
atic function and histology [33]. Similarly, we are convinced that a deeper study of the func-
tional features of islet β-cells [34, 35]induced by MSG would be a mechanistic development of
our observation but this possibility was not included in the prior aims and scopes of this study.
Of note, the dose given to rats is 5–6 times higher than the current average estimate of MSG
consumption in Asia (4 g/day)[36] and 2–3 times higher than what is considered as safe (150
mg/kg, 10 g/day for a 70 kg man)[37]. However, the dose given to rats in this study is closer to
the daily amount recorded in a subgroup of subjects in our previous study in the Thai popula-
tion (9–14 g/day)[5]
Fig 7. Representative immunohistochemistry (left) and prevalence (right) of 4-HNE staining which was divided into 3 categories (weak, moderate,
and strong) based on its intensity in control versus MSG-treated groups at 1 and 6 months (x200). * P = 0.001.
doi:10.1371/journal.pone.0131595.g007
Fig 8. Pancreatic function in control and MSG-treated groups asmeasured by (A) insulin levels at 1, 3, 6, and 9 months (mean ± SEM) and (B) oral
glucose tolerance test (OGTT) at 9 months(mean ± SD).
doi:10.1371/journal.pone.0131595.g008
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The higher intake of water observed in the MSG-treated rats is probably not related to the
function of pancreatic tissue, but rather to renal tissue. MSG-treated group excreted a greater
volume of urine and sodium per day compared to controls [38]. The higher water intake is
likely a response by the rats to balance the higher volume loss via urine excretion. It should be
noted that in the rodent model, the effect of MSG on obesity and/or metabolic syndrome dur-
ing adulthood is different from that in the perinatal period of development, a time when the
blood-brain barrier is immature and most vulnerable to toxicity in rodents [39, 40]. At high
concentration, MSG is neurotoxic and destroys cells in the arcuate hypothalamic nuclei, which
is a large hypothalamic area responsible for controlling body weight and energy balance [39].
In contrast, the effects induced by MSG-consumption at adulthood are likely to occur by a dif-
ferent mechanism.
Finally, we are well aware that numerous additional factors may play a pivotal role in the
development or protection of the phenotype observed. First, we recognize that the presence of
NaCl should be addressed in the future by dedicated experiments with equimolar NaCl solu-
tions in animal models [13, 41]. Second, the individual susceptibility to diabetes is necessarily a
key factor and the use of strains prone to metabolic disturbances such as genetically determined
[42]or diet induced [33]obese rat diabetes will prove a much needed proof of this hypothesis,
despite the variable characteristics of these models [43]. Third, additional factors such as pro-
tein intake or drug treatments should also be accounted for in future experiments [14, 44].
Nonetheless, the experimental design to discriminate the effect of all these specific factors must
be prospective and could not be completed in a retrospective fashion.
Conclusion
We demonstrated here that daily MSG consumption increases pancreatic β-cell loss, but this
does not affect baseline insulin levels or glucose tolerance in normal adult rats. While these
results support the argument that MSG is likely to be safe for use in the healthy population,
these results also suggest that significant adverse effects may be seen in subjects with genetic
susceptibility to diabetes or with a preexisting chronic pancreatitis. We also submit that addi-
tional factors not accounted in our experimental design include the individual genetic suscepti-
bility and other nutritional factors which will be the objective of future studies, along with
functional studies of islet cells exposed to MSG.
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